Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX – Get Free Report)’s stock price gapped down prior to trading on Wednesday . The stock had previously closed at $35.99, but opened at $34.23. Nanobiotix shares last traded at $34.5890, with a volume of 7,465 shares changing hands.
Analyst Upgrades and Downgrades
Several equities research analysts have weighed in on NBTX shares. Guggenheim upped their target price on Nanobiotix from $26.00 to $36.00 and gave the stock a “buy” rating in a research note on Thursday, April 2nd. Weiss Ratings reiterated a “sell (d-)” rating on shares of Nanobiotix in a research note on Tuesday, April 21st. UBS Group boosted their price target on Nanobiotix from $3.50 to $30.00 and gave the stock a “neutral” rating in a report on Friday, May 1st. HC Wainwright restated a “buy” rating on shares of Nanobiotix in a research report on Monday, May 18th. Finally, Leerink Partners raised their price objective on Nanobiotix from $37.00 to $46.00 and gave the company an “outperform” rating in a research note on Thursday, June 4th. Four investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $37.33.
Check Out Our Latest Stock Report on Nanobiotix
Nanobiotix Trading Up 0.6%
Nanobiotix (NASDAQ:NBTX – Get Free Report) last issued its quarterly earnings data on Sunday, February 15th. The company reported ($0.23) EPS for the quarter. The company had revenue of $3.42 million for the quarter. Analysts anticipate that Nanobiotix S.A. – Sponsored ADR will post 0.19 earnings per share for the current year.
Institutional Inflows and Outflows
A number of large investors have recently modified their holdings of NBTX. Millennium Management LLC bought a new stake in Nanobiotix during the 4th quarter worth $390,000. Marshall Wace LLP acquired a new position in Nanobiotix in the 4th quarter worth about $220,000. Optiver Holding B.V. bought a new position in Nanobiotix in the third quarter valued at about $101,000. Finally, Royal Bank of Canada raised its position in Nanobiotix by 2,000.0% in the fourth quarter. Royal Bank of Canada now owns 2,625 shares of the company’s stock valued at $61,000 after purchasing an additional 2,500 shares during the last quarter. 38.81% of the stock is currently owned by institutional investors.
About Nanobiotix
Nanobiotix is a clinical-stage biotechnology company headquartered in Paris, France, specializing in the development of novel nanopharmaceuticals to improve cancer treatment. The company’s lead product, NBTXR3, is a first-in-class radioenhancer composed of hafnium oxide nanoparticles designed to amplify the effect of radiotherapy on tumor cells while sparing surrounding healthy tissue. Nanobiotix has established clinical programs across multiple cancer indications, including soft tissue sarcoma, head and neck cancer, and hepatocellular carcinoma.
Since its inception, Nanobiotix has advanced NBTXR3 through pivotal trials and secured CE Mark approval in Europe for the treatment of soft tissue sarcoma.
Featured Articles
- Five stocks we like better than Nanobiotix
- Credo Technologies Accelerates AI—Its Stock Price Will Follow
- Qualcomm Goes All-In: The $10B Bet to Crush NVIDIA
- Jabil Just Gave Investors a Stronger Reason to Buy the Dip
- CarMax In Reverse? Why You Should Buy Now Before the Big Catalysts Emerge
Receive News & Ratings for Nanobiotix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nanobiotix and related companies with MarketBeat.com's FREE daily email newsletter.
